全文获取类型
收费全文 | 338篇 |
免费 | 29篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 4篇 |
妇产科学 | 5篇 |
基础医学 | 7篇 |
口腔科学 | 11篇 |
临床医学 | 36篇 |
内科学 | 8篇 |
皮肤病学 | 5篇 |
神经病学 | 4篇 |
特种医学 | 3篇 |
外科学 | 61篇 |
综合类 | 57篇 |
预防医学 | 18篇 |
眼科学 | 13篇 |
药学 | 132篇 |
中国医学 | 6篇 |
肿瘤学 | 3篇 |
出版年
2024年 | 1篇 |
2023年 | 5篇 |
2022年 | 10篇 |
2021年 | 17篇 |
2020年 | 16篇 |
2019年 | 8篇 |
2018年 | 13篇 |
2017年 | 20篇 |
2016年 | 26篇 |
2015年 | 17篇 |
2014年 | 35篇 |
2013年 | 39篇 |
2012年 | 23篇 |
2011年 | 16篇 |
2010年 | 11篇 |
2009年 | 4篇 |
2008年 | 6篇 |
2007年 | 13篇 |
2006年 | 7篇 |
2005年 | 8篇 |
2004年 | 9篇 |
2003年 | 2篇 |
2002年 | 5篇 |
2001年 | 3篇 |
2000年 | 4篇 |
1999年 | 5篇 |
1998年 | 7篇 |
1997年 | 6篇 |
1996年 | 7篇 |
1995年 | 10篇 |
1994年 | 6篇 |
1993年 | 4篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 4篇 |
排序方式: 共有373条查询结果,搜索用时 15 毫秒
51.
目的 观察酮咯酸氨丁三醇注射液用于无痛胃镜检查超前镇痛的临床效果。方法 选择2010年10月—2011年10月保定市急救中心无痛胃镜检查患者120例,随机分为观察组和对照组,观察组60例,术前30 min im酮咯酸氨丁三醇注射液60 mg;对照组60例,术前未用任何镇痛药。比较两组患者术前、术中、术后的血压(SBP)、心率(HR)、血氧饱和度(SPO2)、睫毛反射消失时间、术中不适情况、术毕清醒时间、丙泊酚总用量。结果 观察组术中SBP和HR的波动小于对照组;观察组丙泊酚总用药量及术中不适发生例数均小于对照组;观察组睫毛反射消失时间及清醒时间较对照组缩短,以上指标两组比较差异均有显著性(P<0.05)。结论 酮咯酸氨丁三醇注射液用于无痛胃镜超前镇痛检查效果满意,可降低术中不适的发生率,减少丙泊酚用量,缩短苏醒时间。 相似文献
52.
目的:探讨了卡前列素氨丁三醇治疗产后出血高危因素孕妇的疗效观察。方法:回顾性分析我院2010年2月~2013年2月收治的80例产后出血高危因素剖宫产产妇的临床资料,随机分为对照组和观察组,观察组产妇在常规治疗的基础上给予宫体注射卡前列素氨丁三醇治疗,对照组产妇在常规治疗的基础上给予米索前列醇、垂体后叶素宫体注射治疗。结果:产后2h、4h出血量比较,观察组均显著低于对照组,差异有显著性意义(P<0.05);观察组产后出血发生率为12.5%,对照组产后出血发生率为31.91%,两组对比统计学有显著性差异(P<0.05);观察组止血时间显著低于对照组,差异有显著性意义(P<0.05);观察组输血患者2例(5%),输血患者10例(25%),观察组显著低于对照组,两组差异有显著性意义(P<0.05);观察组没有患者行子宫切除术,对照组有2例行子宫切除术,统计学均有显著性差异(P<0.05)。观察组不良反应3例,对照组2例。结论:预防性宫体注射卡前列素氨丁三醇在产后出血高危因素孕妇剖宫产术中能明显减少产后出血量,降低产后出血发生率和输血率,缩短止血时间,减少近远期并发症,值得临床推广。 相似文献
53.
目的:评价酮咯酸氨丁三醇联合丙泊酚静脉麻醉用于无痛肠镜检查的麻醉效果及安全性。方法:选择120例自愿实施无痛肠镜检查患者,随机分为两组,A组仅使用丙泊酚,B组先静脉滴注酮咯酸氨丁三醇30 mg,5 min后静脉推注丙泊酚。记录两组患者在不同时间点的平均动脉压(MAP)、心率(HR)、呼吸(RR)及血氧饱和度(SpO2)数值,比较两组患者的丙泊酚用量、手术时间、术中肢动、清醒时间、疼痛评分。结果:所有患者均顺利完成手术,两组术中的MAP、HR均较术前显著降低(P<0.05),但两组间比较差异无统计学意义(P>0.05)。B组的丙泊酚用量、疼痛评分、麻醉效果显著优于A组(P<0.05)。两组手术时间、清醒时间比较差异无统计学意义(P>0.05)。结论:在无痛肠镜检查中联合应用酮咯酸氨丁三醇-丙泊酚能增强麻醉效果,不增加麻醉风险,术后腹痛减少,患者满意,是一种安全、有效的麻醉方法,值得在临床上推广应用。 相似文献
54.
目的评价酮咯酸氨丁三醇分散片剂的人体相对生物利用度,并与胶囊剂比较其生物等效性。方法 18名男性健康受试者随机、自身对照交叉单剂量口服酮咯酸氨丁三醇分散片和胶囊,采用RP-HPLC法测定血浆中酮咯酸氨丁三醇的浓度。结果单剂量口服含酮咯酸氨丁三醇20 mg的受试和参比制剂,其达峰时间Tmax分别为(0.68±0.30)、(0.80±0.38)h;血药浓度峰值Cmax分别为(3 124.44±382.96)、(3 170.28±289.03)ng/mL;药时曲线下面积AUC(0→24)分别为(13 939.32±2 471.53)、(14 312.29±2 268.26)ng.h/mL。两种制剂的药物动力学参数比较差异无统计学意义(P>0.05),受试制剂的相对生物利用度(F)为97.86%±11.62%。结论两种制剂具有生物等效性。 相似文献
55.
目的探讨肌内注射酮咯酸氨丁三醇注射液急诊治疗肾绞痛的效果。方法将肾绞痛患者108例随机分为两组,观察组56组例,对照组52例,观察组采用酮咯酸氨丁三醇注射液30mg肌内注射;对照组强痛定50mg肌内注射。结果观察组的临床总有效率明显比对照组(P〈0.01),起效及显效时间快差异有统计学意义(P〈0.01),不良反应小。结论采用肌内注射酮咯酸氨丁三醇注射液能有效提高止痛效果,起效快,不良反应小,值得临床推广。 相似文献
56.
Juan Rodríguez‐Silverio María Elena Sánchez‐Mendoza Jesús Arrieta‐Valencia Héctor Isaac Rocha‐Gonzalez Francisco Javier Flores‐Murrieta 《Drug development research》2013,74(1):38-42
Preclinical Research |
57.
《Journal of drug targeting》2013,21(6):551-563
AbstractThe objective of this study was to formulate novel painless combined hyaluronic acid (HA)–ketorolac (KT) membrane for the management of osteoarthritis with rapid analgesic onset, thus avoiding HA frequent invasive intra-articular injections and KT gastrointestinal complaints associated with all non-steroidal anti-inflammatory drugs. HA was chemically crosslinked with carbodiimide/glutaraldehyde to yield membrane of low water content. Different in vitro aspects (mechanical properties, water content and in vitro release) were studied leading to an optimized soft, flexible K8 HA membrane containing 30?mg KT that achieved the desired balance of excellent elasticity and low water content. Moreover, a successful retardation of KT release rate was achieved (82%) after 48?h with favored initial fast drug release in the first hour (32.7%) to attain rapid analgesic effect. The clinical assessments in arthritic rats revealed apparent improvement in joint space narrowing, highest increase in bone mineral density at the proximal tibia and distal femur joints with the absence of osteophytosis only in animal group treated with combined HA–KT membrane. Application of K8 membrane was able to preserve KT plasma concentration above its minimum effective concentration for 48?h therefore, would able to replace six commercial tablets each of 10?mg KT. 相似文献
58.
《Drug delivery》2013,20(3):320-327
AbstractObjectives: The efficacy of ketorolac tromethamine (KT) floating alginate beads as a drug delivery system for better control of KT release was investigated. The formulation with the highest drug loading, entrapment efficiency, swelling, buoyancy, and in vitro release would be selected for further in vivo analgesic effect in the mice and pharmacokinetics study in rats compared to the tablet dosage form.Methods: KT floating alginate beads were prepared by extrusion congealing technique. KT in plasma samples was analyzed using a UPLC MS/MS assay.Results: The percentage yield, drug loading and encapsulation efficiency were increased proportionally with the hydroxypropylmethyl cellulose (HPMC) polymer amount in the KT floating beads. A reverse relationship was observed between HPMC amount in the beads and the KT in vitro release rate. F3-floating beads were selected, due to its better in vitro results (continued floating for >8?h) than others. A longer analgesic effect was observed for F3 in fed mice as compared to the tablets. After F3 administration to rats, the Cmax (2.2?±?0.3?µg/ml) was achieved at ~2?h and the decline in KT concentration was slower. F3 showed a significant increase in the AUC (1.89 fold) in rats as compared to the tablets.Conclusion: KT was successfully formulated as floating beads with prolonged in vitro release extended to a better in vivo characteristic with higher bioavailability in rats. KT in floating beads shows a superior analgesic effect over tablets, especially in fed mice. 相似文献
59.
《Expert opinion on drug delivery》2013,10(9):961-975
Ketorolac tromethamine (KT) is a non-steroidal anti-inflammatory drug that belongs to the class of heteroaryl acetic acid derivatives. It is a non-selective cyclooxygenase (COX) inhibitor, being marketed in the racemate form. Most of its analgesic and COX inhibitory activity is retained in the S-isomer. Ketorolac is administered as its tromethamine salt orally, intramuscularly, intravenously and as a topical ophthalmic solution. The frequent occurrence of gastrointestinal disturbances including gastrointestinal bleeding, perforation and peptic ulceration along with the short mean plasma half-life (t1/2 ~ 5.5 h) has prompted for the development of various formulation strategies for the appropriate delivery of KT. The article gives an overview of the main concepts used thus far to design various pharmaceutical dosage forms for the therapeutically effective delivery of the drug candidate through various routes. At present, a great deal of emphasis is being placed on the development of sustained release forms for the drug as this would aid in achieving the required therapeutic efficacy and better tolerance with fewer gastrointestinal side effects. 相似文献
60.
Erin M. Corsini Wayne L. Hofstetter 《The Journal of thoracic and cardiovascular surgery》2021,161(2):448-454
ObjectivesRecent evidence has shown an association between postoperative ketorolac use and anastomotic leak in patients undergoing intestinal and colorectal operations, but this relationship has been minimally explored after esophagectomy. As the use of nonopioid pain control and enhanced recovery protocols is increasingly prioritized, determination of a possible correlation between perioperative ketorolac use and leak is essential.MethodsRecords of patients undergoing esophagectomy for adenocarcinoma at a single institution from 2006 to 2018 reviewed for occurrence of anastomotic leak. Institutional pharmacy records were queried for ketorolac administration during the surgical case through the time of discharge. Multivariable logistic regression was used to determine the relationship between ketorolac administration and anastomotic leak.ResultsA total of 1019 patients met inclusion criteria, the majority of whom were male (907, 89%) with a median age of 62 years. Patients predominantly presented with locoregionally advanced disease and were treated with initial chemoradiation. Ketorolac was administered to 686 patients (67%); use was observed to increase over the study period from 49% in 2006 to 92% in 2016. Conversely, anastomotic leak occurred in 87 patients (9%) overall and decreased over time from 15% (11/72) in 2006 to 2% (2/83) in 2018. Upon multivariable analysis, neither ketorolac administration evaluated as a categoric variable (odds ratio, 0.99; P = .958) or as a continuous variable using dose (odds ratio, 1.00; P = .843) demonstrated an association with anastomotic leak.ConclusionsKetorolac in the postoperative period after esophagectomy has become an integral component of enhanced recovery pathways and does not appear to be associated with anastomotic leak. 相似文献